290 related articles for article (PubMed ID: 8654369)
21. Incidence of RET mutations in patients with Hirschsprung's disease.
Sancandi M; Ceccherini I; Costa M; Fava M; Chen B; Wu Y; Hofstra R; Laurie T; Griffths M; Burge D; Tam PK
J Pediatr Surg; 2000 Jan; 35(1):139-42; discussion 142-3. PubMed ID: 10646792
[TBL] [Abstract][Full Text] [Related]
22. [Mutations of RET proto-oncogene in Hirschsprung disease].
Lyonnet S; Edery P; Mulligan LM; Pelet A; Dow E; Abel L; Holder S; Nihoul-Fékéte C; Ponder BA; Munnich A
C R Acad Sci III; 1994 Apr; 317(4):358-62. PubMed ID: 8000915
[TBL] [Abstract][Full Text] [Related]
23. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
[TBL] [Abstract][Full Text] [Related]
24. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
Takahashi M; Iwashita T; Santoro M; Lyonnet S; Lenoir GM; Billaud M
Hum Mutat; 1999; 13(4):331-6. PubMed ID: 10220148
[TBL] [Abstract][Full Text] [Related]
25. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
Caron P; Attié T; David D; Amiel J; Brousset F; Roger P; Munnich A; Lyonnet S
J Clin Endocrinol Metab; 1996 Jul; 81(7):2731-3. PubMed ID: 8675603
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M
Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain.
Iwashita T; Murakami H; Asai N; Takahashi M
Hum Mol Genet; 1996 Oct; 5(10):1577-80. PubMed ID: 8894691
[TBL] [Abstract][Full Text] [Related]
28. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.
Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H
Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928
[TBL] [Abstract][Full Text] [Related]
29. RET mutations in human disease.
Pasini B; Ceccherini I; Romeo G
Trends Genet; 1996 Apr; 12(4):138-44. PubMed ID: 8901418
[TBL] [Abstract][Full Text] [Related]
30. Long segment and short segment familial Hirschsprung's disease: variable clinical expression at the RET locus.
Edery P; Pelet A; Mulligan LM; Abel L; Attié T; Dow E; Bonneau D; David A; Flintoff W; Jan D
J Med Genet; 1994 Aug; 31(8):602-6. PubMed ID: 7815416
[TBL] [Abstract][Full Text] [Related]
31. Loss of function effect of RET mutations causing Hirschsprung disease.
Pasini B; Borrello MG; Greco A; Bongarzone I; Luo Y; Mondellini P; Alberti L; Miranda C; Arighi E; Bocciardi R
Nat Genet; 1995 May; 10(1):35-40. PubMed ID: 7647787
[TBL] [Abstract][Full Text] [Related]
32. A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.
Califano D; D'Alessio A; Colucci-D'Amato GL; De Vita G; Monaco C; Santelli G; Di Fiore PP; Vecchio G; Fusco A; Santoro M; de Franciscis V
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7933-7. PubMed ID: 8755580
[TBL] [Abstract][Full Text] [Related]
33. Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting.
Peretz H; Luboshitsky R; Baron E; Biton A; Gershoni R; Usher S; Grynberg E; Yakobson E; Graff E; Lapidot M
Hum Mutat; 1997; 10(2):155-9. PubMed ID: 9259198
[TBL] [Abstract][Full Text] [Related]
34. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
Asai N; Murakami H; Iwashita T; Takahashi M
J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
[TBL] [Abstract][Full Text] [Related]
35. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease.
Attié T; Pelet A; Edery P; Eng C; Mulligan LM; Amiel J; Boutrand L; Beldjord C; Nihoul-Fékété C; Munnich A
Hum Mol Genet; 1995 Aug; 4(8):1381-6. PubMed ID: 7581377
[TBL] [Abstract][Full Text] [Related]
36. The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.
Kusafuka T; Puri P
Pediatr Surg Int; 1997; 12(1):11-8. PubMed ID: 9035202
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
[TBL] [Abstract][Full Text] [Related]
38. RET tyrosine kinase signaling in development and cancer.
Arighi E; Borrello MG; Sariola H
Cytokine Growth Factor Rev; 2005; 16(4-5):441-67. PubMed ID: 15982921
[TBL] [Abstract][Full Text] [Related]
39. The physical map of the human RET proto-oncogene.
Pasini B; Hofstra RM; Yin L; Bocciardi R; Santamaria G; Grootscholten PM; Ceccherini I; Patrone G; Priolo M; Buys CH
Oncogene; 1995 Nov; 11(9):1737-43. PubMed ID: 7478601
[TBL] [Abstract][Full Text] [Related]
40. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes.
Xing S; Smanik PA; Oglesbee MJ; Trosko JE; Mazzaferri EL; Jhiang SM
Endocrinology; 1996 May; 137(5):1512-9. PubMed ID: 8612479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
